Bio-Rad Laboratories Inc. (BIO)
NYSE
381.76
+1.73 (+0.46%)
Closed
Aug 24, 2026
Day's Range
373.40384.09
52 wk Range
236.73385.92
Financial Statements - BIO - Bio-Rad Laboratories Inc.
Revenue
2.58B▲ 0.7%
Net Income
759.90M▲ 141.2%Net Margin 29.4%
EBITDA
480.70M▼ 4.7%
Free Cash Flow
374.60M▲ 40.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.58B | 2.56B | 2.67B | 2.80B | 2.92B | 2.54B |
| Cost of Goods | 1.24B | 1.18B | 1.24B | 1.23B | 1.28B | 1.10B |
| Gross Profit | 1.33B | 1.37B | 1.42B | 1.56B | 1.63B | 1.43B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 218.60M | 269M | 337.79M | 475.11M | 500.33M | 421.32M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 730.40M | -2.64B | -1.23B | -5.19B | 4.93B | 4.50B |
| Pre Tax Income | 995.50M | -2.34B | -850.10M | -4.70B | 5.44B | 4.91B |
| Income Tax | 235.60M | -498.30M | -212.78M | -1.07B | 1.19B | 1.10B |
| Net Income | 759.90M | -1.84B | -637.32M | -3.62B | 4.25B | 3.81B |
| EPS Basic | 27.87 | -65.36 | -21.82 | -121.79 | 142.33 | 127.86 |
| EPS Diluted | 27.85 | -65.36 | -21.82 | -121.79 | 140.56 | 126.2 |
| Basic Shares Outstanding | 27.26M | 28.21M | 29.20M | 29.78M | 29.83M | 29.76M |
| Diluted Shares Outstanding | 27.26M | 28.21M | 29.20M | 29.78M | 29.83M | 29.76M |
| Ebit | 1.04B | -2.29B | -800.66M | -4.66B | 5.45B | 4.93B |
| Ebitda | 480.70M | 504.20M | 586.93M | 672.69M | 657.51M | 576.31M |
| Net Income Continuous Operations | 759.90M | -1.84B | -637.30M | -3.62B | 4.25B | 3.81B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
